InfuSystem Holdings, Inc. (NYSEAMERICAN:INFU) Director Christopher R. Sansone Sells 40,838 Shares

InfuSystem Holdings, Inc. (NYSEAMERICAN:INFUGet Rating) Director Christopher R. Sansone sold 40,838 shares of the company’s stock in a transaction on Thursday, November 17th. The shares were sold at an average price of $8.19, for a total value of $334,463.22. Following the completion of the transaction, the director now directly owns 187,280 shares in the company, valued at approximately $1,533,823.20. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

InfuSystem Stock Up 4.4 %

Shares of INFU opened at $8.23 on Tuesday. The company has a current ratio of 1.59, a quick ratio of 1.25 and a debt-to-equity ratio of 0.72. InfuSystem Holdings, Inc. has a 12 month low of $6.10 and a 12 month high of $18.35. The stock’s 50 day moving average is $8.74 and its two-hundred day moving average is $9.12. The firm has a market cap of $170.00 million, a P/E ratio of -274.33 and a beta of 1.18.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 7th.

Institutional Trading of InfuSystem

Several institutional investors have recently bought and sold shares of INFU. Amalgamated Bank purchased a new position in shares of InfuSystem in the first quarter valued at approximately $29,000. Cubist Systematic Strategies LLC purchased a new stake in InfuSystem in the third quarter valued at $82,000. Paradigm Capital Management Inc. NY acquired a new stake in shares of InfuSystem in the third quarter valued at $140,000. Rhumbline Advisers grew its stake in shares of InfuSystem by 44.8% in the first quarter. Rhumbline Advisers now owns 16,232 shares of the medical instruments supplier’s stock valued at $159,000 after buying an additional 5,021 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in InfuSystem during the 3rd quarter worth about $192,000. 54.51% of the stock is owned by institutional investors and hedge funds.

About InfuSystem

(Get Rating)

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.

See Also

Insider Buying and Selling by Quarter for InfuSystem (NYSEAMERICAN:INFU)

Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.